Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

Exclusion Criteria

• •Any neurological condition that may place the subject at increased risk with exposure to Botulinum Toxin Type A, including peripheral motor neuropathic diseases such as amyotrophic lateral sclerosis and motor neuropathy, and neuromuscular junctional disorders such as Lambert-Eaton syndrome and myasthenia gravis
• •Muscle weakness or paralysis, particularly in the area receiving study treatment
• •Active disease or irritation at the treatment areas including the eye and the skin
• •Pregnant, nursing, or planning a pregnancy during the study; or is a woman of child bearing potential (WOCBP) but is not willing to use an effective method of birth control
• •Previous participation in a RT001 clinical study
• •Previous treatment with botulinum toxin (any serotype)